A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee | Completed
A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee

Trial Source

There is no location for this trial

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Health Conditions
  • Osteoarthritis, Knee
  • Musculoskeletal Diseases
Unfortunately contact details are not available for this trial.
Primary Contact Details
Completed
Recruitment Status
NCT00131352
Primary Trial ID Number
Summary
This clinical study is to evaluate the safety and efficacy of hylan G-F 20 (Synvisc) in patients with symptomatic knee osteoarthritis (OA). Patients will be given 6 mL of hylan G-F 20 (Synvisc) (or a phosphate buffered saline control), with a possible repeat treatment with Synvisc after the week 26 visit.
Research Details
  • The trial included an initial 26 week treatment with 6 mL of hylan G-F 20 (Synvisc) (or a phosphate buffered saline control) followed by a 4 week repeat treatment of Synvisc.
Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Study Type
Interventional
Intervention
Device : hylan G-F 20, Other : Phosphate Buffered Saline

Study Arm Groups : Synvisc, Saline Control

Intervention Type
See Interventions above
Primary Outcome Measures
  • Change From Baseline in Knee Pain Over the Course of the 26-week Initial Treatment Period As Measured by Participants Using the Western Ontario and McMaster Universities Osteoarthritis Index Likert Scale Version 3.1 (WOMAC LK 3.1) A (Pain) Subscale; Day 0, up to week 26
Secondary Outcome Measures
  • Change From Baseline in Knee Pain at Week 26 As Measured by Participants Using the Western Ontario and McMaster Universities Osteoarthritis Index Likert Scale Version 3.1 (WOMAC LK 3.1) A (Pain) Subscale; Day 0, Week 26; Participants Level of Pain While Walking at Week 26 As Measured by Participants Using the Western Ontario and McMaster Universities Osteoarthritis Index Likert Scale Version 3.1 (WOMAC LK 3.1) A1 (Walking Pain) Subscale; Week 26; Change From Baseline Over the Course of the 26-week Initial Treatment Period in Physical Function Measured by Participants Using the Western Ontario and McMaster Universities Osteoarthritis Index Likert Scale (WOMAC LK Version 3.1) C (Function) Subscale; Day 0, up to week 26; Change From Baseline at Week 26 in Physical Function Measured by Participants Using the Western Ontario and McMaster Universities Osteoarthritis Index Likert Scale (WOMAC LK Version 3.1) C (Function) Subscale; Day 0, Week 26; Participant Global Assessment (PTGA) of the Target Knee Osteoarthritis Condition at Week 26; Week 26; Clinical Observer Global Assessment (COGA) of the Target Knee Osteoarthritis (OA) Condition at Week 26; Week 26; Participants Classified as Responders Per the Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Criteria at Week 26; Week 26
Publication(s)
Sorry, this information is not available
Result Reports
This is available on the Clinicaltrials.gov website
Gender
Both
Age Range
40 Years - N/A
Who Can Participate
Patients
Number of Participants
Sorry, this information is not available
Participant Inclusion Criteria
  • Inclusion Criteria:
  • - Patient with documented diagnosis of primary osteoarthritis (OA) of the target knee
  • made at least 3 months prior to Screening,
  • - Has radiographic evidence of OA in the tibio-femoral compartment of the target, knee
  • with at least 1 definite osteophyte and a measureable joint space, as diagnosed by
  • standard X-rays taken not longer than 3 months prior to Screening, and before any
  • baseline assessment,
  • - Has continued target knee pain despite conservative treatment (e.g. weight reduction,
  • physical therapy, analgesics),
  • - Has pain in the target knee as demonstrated by a score of 2 or 3 on the Western
  • Ontario and McMaster Universities Osteoarthritis Index Likert Scale Version 3.1
  • (WOMAC LK 3.1) A1 (Walking Pain) Subscale ,
  • - Has a mean score of 1.5 to 3.5 on the Western Ontario and McMaster Universities
  • Osteoarthritis Index Likert Scale Version 3.1 (WOMAC LK 3.1) A (Pain) Subscale.
  • - Inclusion Criteria for Repeat Phase: Must have no major safety concerns during the
  • first course of treatment as assessed by the Investigator; Must have a WOMAC LK 3.1 A
  • score of at least 1.
  • Exclusion criteria:
  • - Has modified Kellgren-Lawrence Numerical Grading System of grade IV in the
  • patello-femoral compartment of the target knee confirmed by standard X-rays taken not
  • longer than 3 months prior to Screening, and before any baseline assessment,
  • - Has clinically apparent tense effusion of the target knee,
  • - Has had viscosupplementation in any joint including the target knee within 9 months
  • prior to Screening,
  • - Has concomitant inflammatory disease or other condition that affects the joints (e.g.
  • rheumatoid arthritis, metabolic bone disease, psoriasis, gout, symptomatic
  • chondrocalcinosis and active infection, etc.,)
  • - Symptomatic OA of the contralateral knee or of either hip that is not responsive to
  • paracetamol and requires other therapy,
  • - Has related hypersensitivities to avian proteins and/or any components of
  • hyaluronan-based injection devices,
Participant Exclusion Criteria
This is in the inclusion criteria above
Trial Location(s)
Nuffield Orthopaedic Centre, Biomedical Research Unit (BRU)
Oxford
England
OX3 7LD
Freeman Hospital
Newcastle-Upon-Tyne
England
NE7 7DN
University Hospital of Wales
Cardiff
Wales
CF14 4XW
Guy's King's and St. Thomas' School of Medicine
London
SE5 9RJ
Manchester
M41 5SL
Trial Contact(s)
Primary Trial Contact
Sorry, this information is not available
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
Belgium, Czech Republic, France, Germany, Netherlands, United Kingdom
Scientific Title
A Multi-Centre, Parallel, Double-Blind, Blinded Evaluator, Randomised, Placebo-Controlled Evaluation of the Efficacy and Safety of a Single Dose of 6 mL of Synvisc in Patients With Symptomatic Osteoarthritis of the Knee
EudraCT Number
Not available for this trial
Funder(s)
    Sorry, this information is not available
Other Study ID Numbers
SYNV00704
Sponsor(s)
Genzyme, a Sanofi Company
Key Dates

Recruitment Start Date

May 2005

Recruitment End Date

Sep 2006

Trial Start Date
Date Not Available
Trial End Date
Date Not Available
Date Assigned

17 Aug 2005

Last Updated

17 Mar 2015